Participated · Series A · Mar 2023

Curreio is a biotechnology company that provides Cryo‑Electron Microscopy (Cryo‑EM) structural‑analysis technology to accelerate drug discovery. The company determines high‑resolution structures of disease target proteins and ligand complexes, with particular strength on integral membrane protein families. Over the past three years Curreio has worked on more than 20 protein targets and solved structures for over 80% of them; roughly 70% of targets were integral membrane proteins. It integrates Cryo‑EM outputs with AI‑driven computational chemistry to increase hit rates while lowering R&D time and cost, and currently has four ongoing R&D projects. The team reports having extended its platform to analyze lower‑molecular‑weight targets (approximately 60 kDa) with ligands (publication in preparation). Curreio plans to use recent financing to further accelerate R&D programs and broaden its Cryo‑EM platform applicability.